



# PRODRUGS OF CARBOXYLIC ACIDS

- Ester formation is the most common prodrug design strategy to increase lipophilicity by masking carboxylic acids, phosphates, and other charged groups.
- Such prodrug is activated by enzymatic (esterase) or chemical hydrolysis.
- Ester prodrugs are most often used to enhance oral absorption and thus passive membrane permeability of poorly permeable compounds.

- Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and some types of chronic heart failure.
- As a prodrug, enalapril is metabolised *in vivo* to the active form enalaprilat and ethanol by various esterases.
- Enalaprilat has potent therapeutic activity when administered intravenously, but its high polarity causes it to be poorly absorbed from gastrointestinal tract.
- Esterification of enalaprilat to enalapril enhances the affinity for the intestinal peptide carrier-mediated transport system, increasing the intestinal absorption and resulting in improved bioavailability.



- Oseltamivir is an ethyl ester prodrug of oseltamivir carboxylate, requiring ester hydrolysis for conversion to the active form.
- Oseltamivir is readily absorbed from gastrointestinal tract after oral administration and converted by hepatic esterases to oseltamivir carboxylate with an absolute bioavailability of 80%.
- Oseltamivir carboxylate is a potent carboxylic transition-state analog inhibitor of influenza virus, neuraminidase, with activity against both influenza A and B viruses.



- Ximelagatran was designed to increase the bioavailability of melagatran, which was the first member of orally administered potent thrombin inhibitors.
- The double prodrug ximelagatran is composed of an ethyl ester group in place of the carboxylic acid and an N- hydroxyamidine group in the amidine end of melagatran.
- By adding these groups, the highly hydrophilic and charged melagatran is converted into a much more lipophilic molecule that is uncharged at physiological pH.
- Ximelagatran increased bioavailability to 18-24% and also improved pharmacokinetic properties relating to lower variability in bioavailability and lack of food effects.
- The formation of melagatran from ximelagatran requires two metabolic reactions. The ester group is cleaved by esterases and N- hydroxyamidine group is reduced to an amidine group in the liver.

